These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

219 related items for PubMed ID: 28928170

  • 1. Effect of adding bezafibrate to standard lipid-lowering therapy on post-fat load lipid levels in patients with familial dysbetalipoproteinemia. A randomized placebo-controlled crossover trial.
    Koopal C, Marais AD, Westerink J, van der Graaf Y, Visseren FLJ.
    J Lipid Res; 2017 Nov; 58(11):2180-2187. PubMed ID: 28928170
    [Abstract] [Full Text] [Related]

  • 2. Effect of evolocumab on fasting and post fat load lipids and lipoproteins in familial dysbetalipoproteinemia.
    Heidemann BE, Koopal C, Roeters van Lennep JE, Stroes ESG, Riksen NP, Mulder MT, -van der Zee LCVV, Blackhurst DM, Marais AD, Visseren FLJ.
    J Clin Lipidol; 2023 Nov; 17(1):112-123. PubMed ID: 36384662
    [Abstract] [Full Text] [Related]

  • 3. Composition and distribution of lipoproteins after evolocumab in familial dysbetalipoproteinemia: A randomized controlled trial.
    Heidemann BE, Marais AD, Mulder MT, Visseren FLJ, Roeters van Lennep JE, Stroes ESG, Riksen NP, van Vark-van der Zee LC, Blackhurst DM, Koopal C.
    J Clin Lipidol; 2023 Nov; 17(5):666-676. PubMed ID: 37517914
    [Abstract] [Full Text] [Related]

  • 4. Vascular risk factors, vascular disease, lipids and lipid targets in patients with familial dysbetalipoproteinemia: a European cross-sectional study.
    Koopal C, Retterstøl K, Sjouke B, Hovingh GK, Ros E, de Graaf J, Dullaart RP, Bertolini S, Visseren FL.
    Atherosclerosis; 2015 May; 240(1):90-7. PubMed ID: 25768710
    [Abstract] [Full Text] [Related]

  • 5. Impact of bezafibrate and atorvastatin on lipoprotein subclass in patients with type III hyperlipoproteinemia: result from a crossover study.
    Kawashiri MA, Kobayashi J, Nohara A, Noguchi T, Tada H, Nakanishi C, Inazu A, Mabuchi H, Yamagishi M.
    Clin Chim Acta; 2011 May 12; 412(11-12):1068-75. PubMed ID: 21354122
    [Abstract] [Full Text] [Related]

  • 6. Effects of two different fibric acid derivatives on lipoproteins, cholesteryl ester transfer, fibrinogen, plasminogen activator inhibitor and paraoxonase activity in type IIb hyperlipoproteinaemia.
    Durrington PN, Mackness MI, Bhatnagar D, Julier K, Prais H, Arrol S, Morgan J, Wood GN.
    Atherosclerosis; 1998 May 12; 138(1):217-25. PubMed ID: 9678787
    [Abstract] [Full Text] [Related]

  • 7. Safety and efficacy of long-term combination therapy with bezafibrate and ezetimibe in patients with dyslipidemia in the prospective, observational J-COMPATIBLE study.
    Teramoto T, Abe K, Taneyama T.
    Cardiovasc Diabetol; 2013 Nov 06; 12():163. PubMed ID: 24195788
    [Abstract] [Full Text] [Related]

  • 8. Simvastatin but not bezafibrate decreases plasma lipoprotein-associated phospholipase A₂ mass in type 2 diabetes mellitus: relevance of high sensitive C-reactive protein, lipoprotein profile and low-density lipoprotein (LDL) electronegativity.
    Constantinides A, de Vries R, van Leeuwen JJ, Gautier T, van Pelt LJ, Tselepis AD, Lagrost L, Dullaart RP.
    Eur J Intern Med; 2012 Oct 06; 23(7):633-8. PubMed ID: 22902096
    [Abstract] [Full Text] [Related]

  • 9. Lipid-lowering therapy does not affect the postprandial drop in high density lipoprotein-cholesterol (HDL-c) plasma levels in obese men with metabolic syndrome: a randomized double blind crossover trial.
    Hajer GR, Dallinga-Thie GM, van Vark-van der Zee LC, Olijhoek JK, Visseren FL.
    Clin Endocrinol (Oxf); 2008 Dec 06; 69(6):870-7. PubMed ID: 18394022
    [Abstract] [Full Text] [Related]

  • 10. Postprandial reverse cholesterol transport in type 2 diabetic patients: effect of a lipid lowering treatment.
    Autran D, Attia N, Dedecjus M, Durlach V, Girard-Globa A.
    Atherosclerosis; 2000 Dec 06; 153(2):453-60. PubMed ID: 11164435
    [Abstract] [Full Text] [Related]

  • 11. The effects of combined treatment with beta 1-selective receptor antagonists and lipid-lowering drugs on fat metabolism and measures of fatigue during moderate intensity exercise: a placebo-controlled study in healthy subjects.
    Eagles CJ, Kendall MJ.
    Br J Clin Pharmacol; 1997 Mar 06; 43(3):291-300. PubMed ID: 9088584
    [Abstract] [Full Text] [Related]

  • 12. Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction.
    Tenenbaum A, Fisman EZ.
    Cardiovasc Diabetol; 2012 Oct 11; 11():125. PubMed ID: 23057687
    [Abstract] [Full Text] [Related]

  • 13. Are high density lipoprotein (HDL) and triglyceride levels relevant in stroke prevention?
    Rizos E, Mikhailidis DP.
    Cardiovasc Res; 2001 Nov 11; 52(2):199-207. PubMed ID: 11684067
    [Abstract] [Full Text] [Related]

  • 14. Comparison of the efficacy of simvastatin and standard fibrate therapy in the treatment of primary hypercholesterolemia and combined hyperlipidemia.
    Bruckert E, De Gennes JL, Malbecq W, Baigts F.
    Clin Cardiol; 1995 Nov 11; 18(11):621-9. PubMed ID: 8590530
    [Abstract] [Full Text] [Related]

  • 15. Bezafibrate improves postprandial hypertriglyceridemia and associated endothelial dysfunction in patients with metabolic syndrome: a randomized crossover study.
    Ohno Y, Miyoshi T, Noda Y, Oe H, Toh N, Nakamura K, Kohno K, Morita H, Ito H.
    Cardiovasc Diabetol; 2014 Apr 05; 13():71. PubMed ID: 24708775
    [Abstract] [Full Text] [Related]

  • 16. Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention?
    Tenenbaum A, Fisman EZ.
    Cardiovasc Diabetol; 2012 Nov 14; 11():140. PubMed ID: 23150952
    [Abstract] [Full Text] [Related]

  • 17. Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and "normal" cholesterol levels. A randomized, placebo-controlled trial. Harvard Atherosclerosis Reversibility Project (HARP) Study Group.
    Pasternak RC, Brown LE, Stone PH, Silverman DI, Gibson CM, Sacks FM.
    Ann Intern Med; 1996 Oct 01; 125(7):529-40. PubMed ID: 8815751
    [Abstract] [Full Text] [Related]

  • 18. The effect of α-cyclodextrin on postprandial lipid and glycemic responses to a fat-containing meal.
    Jarosz PA, Fletcher E, Elserafy E, Artiss JD, Jen KL.
    Metabolism; 2013 Oct 01; 62(10):1443-7. PubMed ID: 23806736
    [Abstract] [Full Text] [Related]

  • 19. The effect of statin alone or in combination with ezetimibe on postprandial lipoprotein composition in obese metabolic syndrome patients.
    Hajer GR, Dallinga-Thie GM, van Vark-van der Zee LC, Visseren FL.
    Atherosclerosis; 2009 Jan 01; 202(1):216-24. PubMed ID: 18533158
    [Abstract] [Full Text] [Related]

  • 20. The effects of low-dose simvastatin and ezetimibe compared to high-dose simvastatin alone on post-fat load endothelial function in patients with metabolic syndrome: a randomized double-blind crossover trial.
    Olijhoek JK, Hajer GR, van der Graaf Y, Dallinga-Thie GM, Visseren FL.
    J Cardiovasc Pharmacol; 2008 Aug 01; 52(2):145-50. PubMed ID: 18670365
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.